BRIEF-Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy

June 9 (Reuters) - Alterity Therapeutics Ltd ATH.AX:

  • ALTERITY THERAPEUTICS ACHIEVES ALIGNMENT WITH U.S. FDA ON PIVOTAL PHASE 3 PROGRAM FOR ATH434 IN MULTIPLE SYSTEM ATROPHY

  • ALTERITY THERAPEUTICS - FDA AGREES TO PHASE 3 DESIGN INCLUDING UMSARS PART I AS PRIMARY ENDPOINT

  • ALTERITY THERAPEUTICS - FDA CONCURS WITH ATH434 50 MG TWICE DAILY DOSE FOR PHASE 3

  • ALTERITY THERAPEUTICS - PHASE 3 TRIAL ACTIVITIES ON TRACK TO INITIATE BY YEAR-END 2026

Source text: ID:nGNX1PfrCK

Further company coverage: ATH.AX


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.